Vaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) Book value per share
Vaxcyte, Inc.'s book value per share at the end of fiscal 2025 was 19.7×, down 27.2% from 27.1× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 19.1×. Over the past ten years it has ranged from 5.5× (fiscal 2021) to 27.1× (fiscal 2024); the current reading is higher than 88% of that period. Vaxcyte, Inc. ranks 37th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 19.7× | (27.18%) |
| FY2024 | 27.1× | 112.24% |
| FY2023 | 12.8× | (13.14%) |
| FY2022 | 14.7× | 168.71% |
| FY2021 | 5.5× | (53.27%) |
| FY2020 | 11.7× | (17.64%) |
| FY2019 | 14.2× | (14.13%) |
| FY2018 | 16.6× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 19.1× | (11.12%) |
| Mar 2026 | 21.5× | 8.83% |
| Dec 2025 | 19.7× | (7.10%) |
| Sep 2025 | 21.2× | (5.92%) |
| 26 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | 32.3× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 21.4× |
| PCVX Vaxcyte, Inc. | 19.1× |
| TECH Bio-Techne Corp compare | 13.5× |
| PTGX Protagonist Therapeutics, Inc. compare | 12.8× |
| TWST Twist Bioscience Corporation compare | 7.1× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| IBRX ImmunityBio, Inc. compare | −1.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))